Free Trial

Harmony Biosciences (HRMY) Stock Price, News & Analysis

Harmony Biosciences logo
$35.60 +0.15 (+0.43%)
As of 10:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Harmony Biosciences Stock (NASDAQ:HRMY)

Key Stats

Today's Range
$35.25
$35.86
50-Day Range
$31.57
$37.52
52-Week Range
$26.47
$41.61
Volume
42,101 shs
Average Volume
663,383 shs
Market Capitalization
$2.04 billion
P/E Ratio
13.63
Dividend Yield
N/A
Price Target
$51.00
Consensus Rating
Buy

Company Overview

Harmony Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
97th Percentile Overall Score

HRMY MarketRank™: 

Harmony Biosciences scored higher than 97% of companies evaluated by MarketBeat, and ranked 51st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Harmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Harmony Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Harmony Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Harmony Biosciences is 13.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.81.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Harmony Biosciences is 13.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.20.

  • Price to Earnings Growth Ratio

    Harmony Biosciences has a PEG Ratio of 0.49. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Harmony Biosciences has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Harmony Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    10.14% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently increased by 19.14%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Harmony Biosciences does not currently pay a dividend.

  • Dividend Growth

    Harmony Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.14% of the float of Harmony Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Harmony Biosciences has a short interest ratio ("days to cover") of 6.4.
  • Change versus previous month

    Short interest in Harmony Biosciences has recently increased by 19.14%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Harmony Biosciences has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Harmony Biosciences this week, compared to 7 articles on an average week.
  • Search Interest

    10 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Harmony Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Harmony Biosciences' insider trading history.
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

HRMY Stock News Headlines

A $674B Industry Missed the Bigger Picture
TV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.
HC Wainwright Issues Positive Estimate for HRMY Earnings
See More Headlines

HRMY Stock Analysis - Frequently Asked Questions

Harmony Biosciences' stock was trading at $34.41 at the beginning of 2025. Since then, HRMY stock has increased by 3.0% and is now trading at $35.45.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its earnings results on Tuesday, May, 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. The company's revenue was up 19.5% compared to the same quarter last year.
Read the conference call transcript
.

Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Harmony Biosciences' top institutional shareholders include Capital Management Corp VA (0.61%), CX Institutional (0.36%), Atle Fund Management AB (0.15%) and Ruffer LLP (0.15%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Sandip Kapadia, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks.
View institutional ownership trends
.

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/06/2025
Today
7/30/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HRMY
CIK
1802665
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$70.00
Low Price Target
$33.00
Potential Upside/Downside
+42.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.62
Trailing P/E Ratio
13.60
Forward P/E Ratio
14.72
P/E Growth
0.49
Net Income
$145.49 million
Net Margins
20.53%
Pretax Margin
26.48%
Return on Equity
24.32%
Return on Assets
15.92%

Debt

Debt-to-Equity Ratio
0.22
Current Ratio
3.67
Quick Ratio
3.63

Sales & Book Value

Annual Sales
$714.73 million
Price / Sales
2.87
Cash Flow
$2.95 per share
Price / Cash Flow
12.14
Book Value
$11.56 per share
Price / Book
3.10

Miscellaneous

Outstanding Shares
57,420,000
Free Float
43,872,000
Market Cap
$2.05 billion
Optionable
Optionable
Beta
0.83

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:HRMY) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners